WASHINGTON — Drug makers have 901 biotech drugs under development for more than 100 diseases ranging from cancers and infectious diseases to autoimmune disorders and cardiovascular diseases, the Pharmaceutical Research and Manufacturers of America said.
Cancer drugs, in particular, have seen tremendous activity, with 353 drugs for cancer and related conditions included on the list. The list also included 69 drugs for autoimmune diseases, 187 for infectious diseases and 59 for cardiovascular diseases. They included 300 monoclonal antibodies, 298 vaccines, 20 interferons and 23 antisense drugs.
“Innovative, targeted therapies offer enormous potential to address unmet medical needs of patients with cancer, HIV/AIDS and many other serious diseases,” PhRMA president and CEO John Castellani said.